A cyclic peptide targeted to the immune checkpoint protein CTLA4 is designed using a hierarchy of computational methods, demonstrated to bind by a physical measurement, and shown to inhibit tumor growth in cell culture and in mice. This evidence concerns the gene CTLA4 and neoplasm.